Evotec Other Current Assets vs Non Current Liabilities Total Analysis
EVO Stock | USD 4.83 0.07 1.47% |
Evotec SE financial indicator trend analysis is much more than just examining Evotec SE ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evotec SE ADR is a good investment. Please check the relationship between Evotec SE Other Current Assets and its Non Current Liabilities Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Other Current Assets vs Non Current Liabilities Total
Other Current Assets vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evotec SE ADR Other Current Assets account and Non Current Liabilities Total. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Evotec SE's Other Current Assets and Non Current Liabilities Total is 0.87. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Evotec SE ADR, assuming nothing else is changed. The correlation between historical values of Evotec SE's Other Current Assets and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Evotec SE ADR are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Other Current Assets i.e., Evotec SE's Other Current Assets and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | 0.87 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Non Current Liabilities Total
Most indicators from Evotec SE's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evotec SE ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Evotec SE's Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Sales General And Administrative To Revenue is likely to grow to 0.26, while Tax Provision is likely to drop about 3.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 618.0M | 751.4M | 781.4M | 820.5M | Depreciation And Amortization | 67.6M | 81.7M | 167.9K | 159.5K |
Evotec SE fundamental ratios Correlations
Click cells to compare fundamentals
Evotec SE Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evotec SE fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.2B | 1.5B | 2.2B | 2.3B | 2.3B | 2.4B | |
Total Stockholder Equity | 477.0M | 722.8M | 1.4B | 1.2B | 1.1B | 1.2B | |
Common Stock Shares Outstanding | 151.5M | 153.8M | 166.4M | 176.7M | 176.9M | 188.3M | |
Liabilities And Stockholders Equity | 1.2B | 1.5B | 2.2B | 2.3B | 2.3B | 2.4B | |
Other Stockholder Equity | 786.9M | 1.0B | 1.4B | 1.4B | 1.4B | 733.8M | |
Other Assets | 58.0M | 62.3M | 79.3M | 1.0 | 1.15 | 1.09 | |
Short Long Term Debt Total | 463.1M | 492.0M | 512.9M | 506.7M | 626.2M | 657.5M | |
Other Current Liab | 53.5M | 61.9M | 63.9M | 78.4M | 73.3M | 77.0M | |
Total Current Liabilities | 179.0M | 208.5M | 324.5M | 337.7M | 464.6M | 487.8M | |
Property Plant And Equipment Net | 239.2M | 337.3M | 484.6M | 650.2M | 806.6M | 846.9M | |
Net Debt | 186.1M | 69.8M | (186.4M) | 91.5M | 115.3M | 121.1M | |
Retained Earnings | (441.2M) | (434.2M) | (216.4M) | (392.4M) | (476.3M) | (500.1M) | |
Accounts Payable | 31.3M | 42.5M | 72.6M | 97.3M | 134.3M | 141.0M | |
Cash | 277.0M | 422.2M | 699.3M | 415.2M | 510.9M | 536.5M | |
Non Current Assets Total | 711.4M | 804.1M | 1.1B | 1.2B | 1.4B | 1.5B | |
Non Currrent Assets Other | 23.7M | 37.4M | 56.8M | 74.1M | 95.2M | 100.0M | |
Cash And Short Term Investments | 321.7M | 492.2M | 858.5M | 730.0M | 604.1M | 634.3M | |
Short Term Investments | 44.6M | 70.1M | 159.2M | 314.8M | 93.2M | 74.6M | |
Non Current Liabilities Total | 524.9M | 531.6M | 533.0M | 732.4M | 714.6M | 750.3M | |
Other Current Assets | 3.8M | 62.8M | 63.6M | 123.0M | 64.1M | 67.3M | |
Total Liab | 703.9M | 740.0M | 857.5M | 1.1B | 1.2B | 1.2B | |
Total Current Assets | 469.5M | 658.8M | 1.1B | 1.1B | 903.2M | 948.3M | |
Short Term Debt | 20.7M | 30.0M | 50.6M | 16.4M | 149.1M | 156.5M | |
Common Stock | 150.9M | 163.9M | 176.6M | 177.0M | 177.2M | 128.1M | |
Current Deferred Revenue | 73.4M | 70.6M | 126.8M | 136.7M | 107.9M | 113.2M | |
Net Receivables | 124.1M | 136.9M | 153.3M | 275.8M | 204.1M | 214.3M | |
Inventory | 10.7M | 13.6M | 25.8M | 29.8M | 30.9M | 32.4M | |
Good Will | 255.9M | 247.4M | 257.6M | 274.8M | 275.6M | 289.4M | |
Intangible Assets | 117.0M | 98.0M | 30.9M | 23.8M | 15.5M | 14.7M | |
Accumulated Other Comprehensive Income | (19.6M) | (37.5M) | (12.6M) | (37.4M) | (30.6M) | (32.2M) | |
Other Liab | 93.2M | 82.6M | 69.6M | 70.7M | 63.6M | 61.8M | |
Net Tangible Assets | 79.0M | 102.9M | 375.9M | 1.1B | 1.3B | 1.3B | |
Long Term Debt | 324.9M | 331.0M | 326.3M | 328.3M | 307.1M | 266.0M | |
Capital Lease Obligations | 131.9M | 145.6M | 150.4M | 176.8M | 189.1M | 125.8M | |
Net Invested Capital | 808.3M | 1.1B | 1.7B | 1.5B | 1.1B | 1.1B | |
Short Long Term Debt | 6.3M | 15.4M | 36.1M | 1.6M | 130.0M | 136.5M | |
Net Working Capital | 290.6M | 450.4M | 776.4M | 736.0M | 438.6M | 421.1M | |
Property Plant Equipment | 89.3M | 238.0M | 335.7M | 484.6M | 557.3M | 585.2M | |
Long Term Investments | 41.3M | 59.0M | 287.0M | 150.3M | 142.1M | 129.9M | |
Capital Stock | 150.9M | 163.9M | 176.6M | 177.0M | 177.2M | 182.3M |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving together with Evotec Stock
0.74 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Evotec Stock
0.91 | PEPG | PepGen | PairCorr |
0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.77 | MREO | Mereo BioPharma Group | PairCorr |
0.75 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.74 | PDSB | PDS Biotechnology Corp | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.